Dario Eklund, Santhera CEO
June 20, 2023 10:55 AM EDTUpdated 06:10 PM
Deals

Swiss biotech un­loads US rights to Duchenne can­di­date for $231M

Paul Schloesser

Associate Editor

San­thera, a Swiss biotech wait­ing to see if the FDA will ap­prove its steroid va­morolone for pa­tients with Duchenne mus­cu­lar dy­s­tro­phy in the fall, is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times